PharmaShots | Incisive News in 3 Shots

Subscribe Now

vocs

Novartis' Adakveo (crizanlizumab) Receives the US FDA's Approval for Reducing the Frequency of VOCs in Sickle Cell Disease

Novartis' Adakveo (crizanlizumab) Receives the US FDA's Approval for Reducing the Frequency of VOCs in Sickle Cell Disease

November 18, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us